Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2.
We introduced the interleukin-2 (IL-2) gene into mouse renal cell carcinoma (RenCa) in order to examine the mechanism of tumor rejection. IL-2 gene-transfected RenCa (RenCa/IL-2Hi) exhibited marked retardation of tumor growth when implanted in a syngeneic host. Growth retardation of RenCa/IL-2Hi was also observed in athymic nude mice even after depletion of natural killer (NK) cells by treatment with anti-asialo GM1 antibody. Histological analysis of RenCa/IL-2Hi tumors disclosed non-specific inflammatory changes in syngeneic hosts. Co-injection of Bacillus Calmette Guerin with RenCa/IL-2Hi considerably enhanced the anti-tumor effects. Taken together, these findings strongly suggest that in situ IL-2 production leads to tumor rejection through non-specific inflammatory responses without participation of T cells and NK cells. On the other hand, the syngeneic mice that had rejected RenCa/IL-2Hi acquired immunity against parental RenCa, suggesting possible participation of memory T cells in the second rejection of the tumor.
Hara
I
I
Department of Urology, Kobe University School of Medicine.
Hotta
H
H
Sato
N
N
Eto
H
H
Arakawa
S
S
Kamidono
S
S
D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000276:immunology*; D005260:Female; D006084:Graft Rejection; D007249:Inflammation / Q000209:etiology; D007376:Interleukin-2 / Q000235:genetics / Q000378:metabolism*; D007680:Kidney Neoplasms / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D013601:T-Lymphocytes / Q000502:physiology; D014162:Transfection
D001500:BCG Vaccine; D007376:Interleukin-2